Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Genotoxicity of 2-(3-chlorobenzyloxy)-6-(piperazinyl)pyrazine, a novel 5-hydroxytryptamine2c receptor agonist for the treatment of obesity: role of metabolic activation.

Kalgutkar AS, Dalvie DK, Aubrecht J, Smith EB, Coffing SL, Cheung JR, Vage C, Lame ME, Chiang P, McClure KF, Maurer TS, Coelho RV Jr, Soliman VF, Schildknegt K.

Drug Metab Dispos. 2007 Jun;35(6):848-58. Epub 2007 Mar 7.

PMID:
17344339
2.

Dual-action hypoglycemic and hypocholesterolemic agents that inhibit glycogen phosphorylase and lanosterol demethylase.

Harwood HJ Jr, Petras SF, Hoover DJ, Mankowski DC, Soliman VF, Sugarman ED, Hulin B, Kwon Y, Gibbs EM, Mayne JT, Treadway JL.

J Lipid Res. 2005 Mar;46(3):547-63. Epub 2004 Dec 16.

3.

Isozyme-nonselective N-substituted bipiperidylcarboxamide acetyl-CoA carboxylase inhibitors reduce tissue malonyl-CoA concentrations, inhibit fatty acid synthesis, and increase fatty acid oxidation in cultured cells and in experimental animals.

Harwood HJ Jr, Petras SF, Shelly LD, Zaccaro LM, Perry DA, Makowski MR, Hargrove DM, Martin KA, Tracey WR, Chapman JG, Magee WP, Dalvie DK, Soliman VF, Martin WH, Mularski CJ, Eisenbeis SA.

J Biol Chem. 2003 Sep 26;278(39):37099-111. Epub 2003 Jul 3.

4.

Pharmacokinetic screening of o-naphthoquinone 5-lipoxygenase inhibitors.

Rakhit A, Kuwahara SK, Jones DR, Soliman VF, Kotake AN, Oglesby TD, Wasley JW, Tripp SL, Douglas FL.

Pharm Res. 1990 Oct;7(10):1071-6.

PMID:
2281039

Supplemental Content

Loading ...
Support Center